JAN (NYSE:JAN – Get Free Report) announced a monthly dividend on Friday, September 11th. Shareholders of record on Friday, October 16th will be given a dividend of $0.0475 per share on Wednesday, October 28th. This represents a $0.57 dividend on an annualized basis and a yield of 2.0%. The ex-dividend date is Friday, October 16th.
JAN Stock Up 0.5%
Shares of JAN stock opened at $28.87 on Wednesday. JAN has a 12 month low of $22.76 and a 12 month high of $32.83. The business has a fifty day simple moving average of $30.12 and a 200 day simple moving average of $28.03.
JAN (NYSE:JAN – Get Free Report) last announced its quarterly earnings results on Tuesday, August 4th. The company reported $0.05 earnings per share for the quarter, missing analysts’ consensus estimates of $0.23 by ($0.18). The company had revenue of $216.46 million for the quarter, compared to analyst estimates of $203.32 million. The business’s quarterly revenue was up 45.4% compared to the same quarter last year. JAN has set its FY 2026 guidance at 0.950-0.980 EPS. As a group, equities research analysts expect that JAN will post 0.97 EPS for the current fiscal year.
Trending Headlines about JAN
- Positive Sentiment: Barclays remains constructive on JAN with an overweight rating, and its revised target still implies approximately 14.3% upside from the referenced $28.87 price.
- Neutral Sentiment: The company’s latest quarter showed strong revenue growth of 45.4% year over year to $216.46 million, above expectations, while earnings per share of $0.05 missed the consensus estimate of $0.23. JAN maintained fiscal 2026 EPS guidance of $0.95 to $0.98.
- Negative Sentiment: The target-price cut from Barclays may reinforce concerns about valuation or execution, particularly as JAN shares remain below their 50-day moving average of $30.12.
JAN Company Profile
JanOne Inc (NYSE: JAN) is a publicly traded company focused on addressing the opioid crisis through the development and commercialization of solutions intended to improve the treatment and prevention of opioid use disorder. The company has described its mission as combining business, technology and scientific initiatives to help reduce opioid-related harm.
JanOne’s activities have included biotechnology and pharmaceutical-development initiatives, as well as investments in technologies and businesses connected with healthcare and financial services.
Recommended Stories
- Five stocks we like better than JAN
- Tax Credit Turmoil: Why Enphase and SolarEdge Face a Tough Road
- A Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?
- Could T-Mobile’s Satellite Competition Fears Create a Buying Opportunity?
- Surgical Precision, Sustainable Returns: Johnson & Johnson Secures Its Cash Flow Runway
Receive News & Ratings for JAN Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for JAN and related companies with MarketBeat.com's FREE daily email newsletter.
